Amunix to Present Preclinical Data on HER2- and EGFR-Targeted T Cell Engagers at AACR Virtual Annual Meeting II
June 22, 2020 09:00 ET
|
Amunix Pharmaceuticals, Inc.
Data demonstrate potential of Amunix’s XPAT platform to significantly widen therapeutic index, and address on-target, off-tumor toxicity that has hindered application of T cell engagers to treat solid...
Amunix Appoints Anne Keane as Senior Vice President of Regulatory and Quality
May 27, 2020 07:00 ET
|
Amunix Pharmaceuticals, Inc.
MOUNTAIN VIEW, Calif., May 27, 2020 (GLOBE NEWSWIRE) -- Amunix Pharmaceuticals, Inc. (“Amunix”), a biopharmaceutical company focused on developing prodrugs to bring the promise of potent...
Teneobio’s Lead Candidate, TNB-383B, Receives Orphan Drug Designation from the FDA for the Treatment of Multiple Myeloma
November 06, 2019 08:00 ET
|
TeneoBio, Inc
NEWARK, Calif., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical-stage biotechnology company developing engineered bispecific antibodies for the treatment of cancer announced today that...
Teneobio Licenses Oncology Multispecific Product to Janssen
September 30, 2019 08:00 ET
|
TeneoBio, Inc
NEWARK, Calif., Sept. 30, 2019 (GLOBE NEWSWIRE) -- Teneobio, Inc., a clinical-stage biotechnology company developing engineered bispecific antibodies for the treatment of cancer announced today that...
Amunix Pharmaceuticals Announces the Appointment of Dr. Maninder Hora as Chief Technical Operations Officer
August 27, 2019 07:03 ET
|
Amunix Pharmaceuticals, Inc.
MOUNTAIN VIEW, Calif., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Amunix Pharmaceuticals, Inc. (“Amunix”), a biopharmaceutical company focused on enabling the promise of potent immune-activating...
Teneobio Doses First Patient in Phase 1 Study of TNB-383B for the Treatment of Patients with Multiple Myeloma
July 15, 2019 08:00 ET
|
TeneoBio, Inc
NEWARK, Calif., July 15, 2019 (GLOBE NEWSWIRE) -- Teneobio, Inc. a clinical-stage biotechnology company developing engineered bispecific antibodies for the treatment of cancer announced today that...
Amunix Pharmaceuticals Announces the Appointment of Dr. Bryan Irving as Chief Scientific Officer
June 26, 2019 07:05 ET
|
Amunix Pharmaceuticals, Inc.
MOUNTAIN VIEW, Calif., June 26, 2019 (GLOBE NEWSWIRE) -- Amunix Pharmaceuticals, Inc. (“Amunix”), a biopharmaceutical company focused on enabling the promise of potent immune-activating...
Amunix Expands Executive Team with Appointment of Dr. Mika Derynck as CMO, Dr. Darcy Mootz as CBO, and Yvonne Li as SVP of Finance
May 14, 2019 08:05 ET
|
Amunix Pharmaceuticals, Inc.
MOUNTAIN VIEW, Calif., May 14, 2019 (GLOBE NEWSWIRE) -- Amunix Pharmaceuticals, Inc. (“Amunix”), a biopharmaceutical company focused on the discovery and development of novel protein therapeutics,...
Teneobio Announces US FDA Approval of the Investigational New Drug Application for TNB-383B and the Initiation of Phase I Clinical Studies in Multiple Myeloma Patients
April 29, 2019 08:00 ET
|
TeneoBio, Inc
NEWARK, Calif., April 29, 2019 (GLOBE NEWSWIRE) -- Teneobio, Inc. and its affiliate TeneoOne, Inc. announced today that their investigational new drug application (IND) for TNB-383B, a bispecific...
Merus Announces Financial Results for the Full Year 2018 and Provides Business Update
April 03, 2019 16:00 ET
|
Merus N.V.
UTRECHT, The Netherlands, April 03, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, “we”, “our” or the “Company”), a clinical-stage immuno-oncology company developing Biclonics®,...